<DOC>
	<DOCNO>NCT00216047</DOCNO>
	<brief_summary>HER2 gene amplification increase VEGF production breast cancer ; combine inhibition HER2 VEGF enhance response xenograft model . The upregulation VEGF HER2-overexpressing breast cancer may contribute aggressive phenotype observe HER2-positive breast cancer . New therapeutic target VEGF and/or receptor may enhance efficacy trastuzumab monotherapy . This trial investigate safety efficacy combine HER2 VEGF inhibition .</brief_summary>
	<brief_title>PTK787 + Trastuzumab HER2 Overexpressing Metastatic Breast Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . PTK787 daily plus trastuzumab 4 mg/kg IV week 1 , follow 2 mg/kg weekly disease evaluation every cycle . Patients may continue treatment disease progression toxicity intervenes . Performance Status : ECOG 0 1 Life Expectancy : Not specify Hematopoietic : - ANC &gt; 1500 mm3 - Platelets &gt; 100,000 mm3 - Hemoglobin &gt; 9 g/dL - PTT INR &lt; 1.5 x ULN Hepatic : - ALT AST &lt; 3 x ULN ( &lt; 5 x ULN patient know liver metastasis ) - Alkaline phosphatase &lt; 2.5 x ULN - Serum bilirubin &lt; 1.5 x ULN Renal : - Serum creatinine &lt; 1.5 x ULN - Proteinuria &lt; 1+ dipstick OR total urinary protein &lt; 500 mg/24 hour measure creatinine clearance ( CrCl ) â‰¥ 50 mL/min Cardiovascular : - No clinically significant cardiac disease ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 6 month . - LVEF &gt; LLN MUGA ECHO ( obtain within 28 day prior register protocol therapy ) Pulmonary : - Not specify</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Histologic cytologic diagnosis breast cancer evidence measurable ( 1 ) unresectable , locally recurrent , ( 2 ) metastatic disease . Locally recurrent disease must amenable resection OR radiation curative intent . Patient 's disease may involve 3 metastatic site . In addition , patient may symptomatic pulmonary metastasis liver metastasis involve &gt; 50 % parenchyma . HER2 gene amplification FISH . HER protein overexpression immunohistochemistry sufficient entry . Negative pregnancy test No prior cytotoxic chemotherapy trastuzumab locally recurrent metastatic disease . No prior treatment VEGF inhibit agent No history presence central nervous system ( CNS ) disease . No forms cancer therapy include radiation , chemotherapy hormonal therapy within 21 day prior register protocol therapy . No major surgery within 28 day prior register protocol therapy . No uncontrolled hypertension ( SBP &gt; 170 , DBP &gt; 90 ) , history labile hypertension history poor compliance antihypertensive therapy . No requirement therapeutic anticoagulation , regular aspirin ( &gt; 325 mg/day ) NSAID use . No current breast feeding . No impairment gastrointestinal ( GI ) function may significantly alter absorption PTK787 . No evidence serious concomitant systemic disorder incompatible study ( discretion investigator ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>